JP Morgan Private Wealth Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,070	Closed	-$232K	–	1287
2017 Q2	$232K	Hold	4,070	–	–	﹤0.01%	1102
2017 Q1	$219K	Hold	4,070	–	–	﹤0.01%	1205
2016 Q4	$232K	Sell	4,070 -1,000	-20%	-$60.5K	﹤0.01%	1109
2016 Q3	$315K	Sell	5,070 -3,810	-43%	-$269K	﹤0.01%	972
2016 Q2	$502K	Sell	8,880 -1,000	-10%	-$60.8K	﹤0.01%	779
2016 Q1	$633K	Buy	+9,880	New	+$799K	0.01%	676

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Private Wealth Advisors's KDNY Position: Q3 2017 in Review

JP Morgan Private Wealth Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2017, closing a stake of 4,070 shares — an estimated $232K sold.

JP Morgan Private Wealth Advisors first reported a position in KDNY in Q1 2016 and held it in 6 quarters. The position peaked at $633K in Q1 2016. 90 funds tracked by Wall St. Rank hold KDNY as of Q3 2017.

JP Morgan Private Wealth Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 4,070 Chinook Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $232K.
JP Morgan Private Wealth Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 6 quarters.
JP Morgan Private Wealth Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $633K in Q1 2016.
90 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2017.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.